Premium
Prognostic value of minimal residual disease measured by fusion‐gene transcript in infants with KMT2A ‐rearranged acute lymphoblastic leukaemia treated according to the MLL‐Baby protocol
Author(s) -
Tsaur Grigory,
Popov Alexander,
Riger Tatiana,
Kustanovich Anatoly,
Solodovnikov Alexander,
Shorikov Egor,
Demina Anna,
Verzhbitskaya Tatiana,
Streneva Olga,
Makarova Olga,
Lapotentova Elena,
Aleinikova Olga,
Miakova Natalia,
Boichenko Elmira,
Kondratchik Konstantin,
Ponomareva Natalia,
Karachunskiy Alexander,
Roumiantsev Alexander,
Fechina Larisa
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17304
Subject(s) - minimal residual disease , medicine , cumulative incidence , oncology , fusion gene , chemotherapy , incidence (geometry) , disease , gene , pediatrics , gastroenterology , biology , leukemia , cohort , genetics , physics , optics
Summary The prognostic value of minimal residual disease (MRD) measured by fusion‐gene transcript (FGT) detection was investigated in 76 infants (aged ≤1 year) with acute lymphoblastic leukaemia (ALL) with lysine methyltransferase 2A ( KMT2A ) rearrangements. Either at the end of induction or at later time‐points, FGT‐MRD‐positivity was associated with poor outcome. FGT‐MRD‐positivity after first consolidation or first high‐risk block detected 46·5% of infants with extremely poor outcome [disease‐free survival (SE) 0·06 (0·06), cumulative incidence of relapse (SE) 0·91 (0·05)], which was also confirmed in multivariable analysis. Thus, FGT‐MRD measurement at a single time‐point clearly identifies infants with ALL who are curable with conventional chemotherapy and those who would benefit only from other treatment approaches.